NASDAQ:TCRX | Free Cash Flow | TScan Therapeutics, Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2020-12-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$24.28M$70,000.00-$24.35M
2025-12-31-$32M$171,000.00-$32.17M
2025-03-31-$37.59M$1.53M-$39.12M
2024-12-31-$27.41M$888,000.00-$28.3M
2024-03-31-$29.27M$705,000.00-$29.97M
2023-12-31-$23.77M$469,000.00-$24.24M
2023-03-31-$23.59M$838,000.00-$24.43M
2022-12-31-$16.01M$1.38M-$17.39M
2022-03-31-$20.12M$531,000.00-$20.66M
2021-12-31-$14.38M$2.21M-$16.59M
2021-03-31-$9.96M$2.96M-$12.92M
2020-12-31-$7.35M$1.39M-$8.74M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$135.32M$4.41M-$139.73M
2024-12-31-$110.82M$3.83M-$114.65M
2023-12-31-$61.36M$3.15M-$64.5M
2022-12-31-$66.5M$4.23M-$70.73M
2021-12-31-$48.68M$9.94M-$58.62M
2020-12-31-$3.02M$4.24M-$7.26M

Research interface only. Not investment advice. Prices are a checked-in snapshot, not live quotes.